Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge.
• The hepatocyte growth factor (HGF)/c-Met signaling pathway is implicated in CRPC progression.
• Targeting key signaling cascades offers a therapeutic strategy for CRPC.

Purpose of the Study:

• To investigate the anti-cancer effects of Evodiamine (EVO) in CRPC.
• To elucidate the impact of EVO on the HGF-induced c-Met/Src/STAT3 signaling axis.
• To assess EVO's ability to inhibit tumor cell survival, proliferation, and angiogenesis.

Main Methods:

• In vitro studies using PC-3 and DU145 CRPC cell lines.
• Assessment of EVO's cytotoxicity and anti-proliferative effects.
• Western blot analysis to evaluate protein phosphorylation and expression.
• Cell cycle analysis and apoptosis assays.
• Small interfering RNA (siRNA) targeting c-Met.

Main Results:

• EVO demonstrated significant cytotoxicity and anti-proliferation activity in CRPC cells.
• EVO inhibited HGF-induced phosphorylation of c-Met, Src, and STAT3.
• EVO impaired STAT3 nuclear translocation and downregulated key oncogenic markers (Bcl-2, Bcl-xL, cyclin D1, COX-2, survivin, VEGF, MMP-9).
• EVO induced cell cycle arrest and apoptosis.
• Knockdown of c-Met using siRNA reduced EVO-mediated Src/STAT3 activation and apoptosis.

Conclusions:

• EVO effectively abrogates the c-Met/Src/STAT3 signaling axis in CRPC cells.
• EVO exhibits potent anti-tumorigenic properties, suppressing proliferation, survival, and angiogenesis.
• EVO represents a promising therapeutic agent for CRPC treatment.